Differences in life expectancy of adrenocortical carcinoma patients vs. age‑ and sex-matched population controls.
Adrenocortical carcinoma
Life tables
Overall survival
SEER
Social security administration
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
31
05
2024
accepted:
06
08
2024
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
11
8
2024
Statut:
aheadofprint
Résumé
To quantify to what extent the 5-year overall survival (OS) of adrenocortical carcinoma (ACC) patients differs from age- and sex-matched population-based controls, especially when stage is considered. We relied on the Surveillance, Epidemiology, and End Results database (2004-2020) to identify newly diagnosed (2004-2014) ACC patients. Subsequently, we compared OS between ACC patients relative to simulated age- and sex-matched controls (Monte Carlo simulation), according to Social Security Administration Life Tables (2004-2020). Of all 742 ACC patients, 301 (41%) harbored localized stage, 173 (23%) locally advanced stage, and 268 (36%) metastatic stage. At 5-years follow-up, ACC patients' OS was 33%. After stratification for stage, the 5-years OS was 55 vs. 31 vs. 8% in localized, locally advanced, and metastatic stages, respectively. Conversely, after Monte Carlo simulation of age- and sex-matched controls, OS at five-years was 93% in the entire simulated cohort vs. 94% in the simulated localized cohort vs. 92 and 92% in locally advanced and metastatic stage, respectively. The resulting differences in OS between ACC patients and age- and sex-matched population-based controls were 60 vs. 39 vs. 61 vs. 84% respectively in the overall cohort vs. localized vs. locally advanced vs. metastatic stage. The most pronounced life expectancy detriment (84%) was recorded in metastatic ACC followed by locally advanced ACC patients (61%). Unfortunately, even in patients with localized ACC, life expectancy was 39% lower than that of the general population. Therefore, regardless of stage, ACC diagnosis results in a very pronounced detriment in life expectancy relative to the general population.
Identifiants
pubmed: 39129040
doi: 10.1007/s11255-024-04180-9
pii: 10.1007/s11255-024-04180-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Fassnacht M, Allolio B (2009) Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23(2):273–289. https://doi.org/10.1016/j.beem.2008.10.008
doi: 10.1016/j.beem.2008.10.008
pubmed: 19500769
SEER, SEER Cancer Statistics Review, 1975–2020. [Online]. https://seer.cancer.gov/index.html .
Social Security Administration, “Actuarial Life Table.
Cano Garcia C et al. (2023) Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities. Int Urol Nephrol 55(5): 1117–1123, https://doi.org/10.1007/s11255-023-03517-0 .
Chierigo F et al (2022) Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. Int Urol Nephrol 54(7):1521–1527. https://doi.org/10.1007/s11255-022-03221-5
doi: 10.1007/s11255-022-03221-5
pubmed: 35508792
Morra S, Piccinelli ML, Garcia CC, Tappero S, Barletta F (2023) Differences in future life expectancy of testicular germ—cell tumor patients vs. age—matched male population—based controls. Int Urol Nephrol 55(12):3119–3128. https://doi.org/10.1007/s11255-023-03763-2
doi: 10.1007/s11255-023-03763-2
pubmed: 37640983
Cano Garcia C et al. (2023) Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States. Ann Epidemiol 79: 65–70, https://doi.org/10.1016/j.annepidem.2023.01.003 .
Preisser F et al (2019) Validation of the social security administration life tables (2004–2014) in localized prostate cancer patients within the surveillance, epidemiology, and end results database. Eur Urol Focus 5(5):807–814. https://doi.org/10.1016/j.euf.2018.05.006
doi: 10.1016/j.euf.2018.05.006
pubmed: 29802052
Piccinelli ML et al. (2023) Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma. Cancers (Basel)., 15(7), https://doi.org/10.3390/cancers15072155 .
Piccinelli ML et al (2023) Assessment of the VENUSS and grant models for individual prediction of cancer-specific survival in surgically treated nonmetastatic papillary renal cell carcinoma. Eur Urol open Sci 53:109–115. https://doi.org/10.1016/j.euros.2023.05.005
doi: 10.1016/j.euros.2023.05.005
pubmed: 37441347
pmcid: 10334233
R: The R Project for Statistical Computing.
Kebebew E, Reiff E, Duh Q-Y, Clark OH, McMillan A (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World J Surg 30(5):872–878. https://doi.org/10.1007/s00268-005-0329-x
doi: 10.1007/s00268-005-0329-x
pubmed: 16680602
Tella SH, Kommalapati A, Yaturu S, Kebebew E (2018) Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database. J Clin Endocrinol Metab 103(9):3566–3573. https://doi.org/10.1210/jc.2018-00918
doi: 10.1210/jc.2018-00918
pubmed: 29982685
Puglisi S et al (2023) New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study. J Clin Endocrinol Metab 108(10):2517–2525. https://doi.org/10.1210/clinem/dgad199
doi: 10.1210/clinem/dgad199
pubmed: 37022947
Kerkhofs TMA et al (2023) Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49(11):2579–2586. https://doi.org/10.1016/j.ejca.2013.02.034
doi: 10.1016/j.ejca.2013.02.034
Panunzio KPA, Barletta F, Tappero S, Cano Garcia C, Piccinelli M, Incesu RB, Law KW, Tian Z, Tafuri A, Tilki D, De Cobelli O, Chun FKH, Terrone C, Briganti A, Saad F, Shariat SF, Bourdeau I, Cerruto MA, Antonelli A, Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis, J Surg Oncol, pp 560–567, 2023, https://doi.org/10.1002/jso.27161 .
Panunzio A et al (2022) Hispanic vs. caucasian race/ethnicity in adrenocortical carcinoma patients. Anticancer Res 42(11):5579–5585. https://doi.org/10.21873/anticanres.16065
doi: 10.21873/anticanres.16065
pubmed: 36288855
Sohail S et al. (2021) Clinical and Histopathological variables and prognostic factors of adrenocortical carcinoma. Cureus, 13(6): e15721, https://doi.org/10.7759/cureus.15721 .
Elhassan YS et al (2021) S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol 186(1):25–36. https://doi.org/10.1530/EJE-21-0510
doi: 10.1530/EJE-21-0510
pubmed: 34709200
pmcid: 8679848
Luconi M et al (2023) Prognostic value of microscopic tumor necrosis in adrenal cortical carcinoma. Endocr Pathol 34(2):224–233. https://doi.org/10.1007/s12022-023-09760-6
doi: 10.1007/s12022-023-09760-6
pubmed: 36952130
pmcid: 10264263
Yi X, Wan Y, Cao W, Peng K, Li X, Liao W (2022) Identification of four novel prognostic biomarkers and construction of two nomograms in adrenocortical carcinoma: a multi-omics data study via bioinformatics and machine learning methods. Front Mol Biosci 9(May):1–17. https://doi.org/10.3389/fmolb.2022.878073
doi: 10.3389/fmolb.2022.878073